Effective oncolytic vaccinia therapy for human sarcomas

Journal of Surgical Research

Volumn 175, Issue 2, 2012, Pages

  He, Shuangba ^a,b   Li, Pingdong ^a,b   Chen, Chun Hao ^a   Bakst, Richard L ^a   Chernichenko, Natalya ^a   Yu, Yong A ^c,d   Chen, Nanhai ^c,d   Szalay, Aladar A ^c,d,e   Yu, Zhenkun ^b   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c GENELUX CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

oncolysis; recombinant; replication competent; virus

Indexed keywords

GLV 1H 68; GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; FIBROHISTIOCYTOMA; FIBROSARCOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; TRANSGENE; TUMOR REGRESSION; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; BONE NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; FIBROSARCOMA; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862813636     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.11.1030     Document Type: Article

References (28)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. N.F. Gilbert, C.P. Cannon, and P.P. Lin Soft-tissue sarcoma J Am Acad Orthop Surg 17 2009 40
3. Z. Yu, S. Li, P. Brader, and N. Chen Oncolytic vaccinia therapy of squamous cell carcinoma Mol Cancer 8 2009 45
4. T.C. Liu, and D. Kirn Gene therapy progress and prospects cancer: Oncolytic viruses Gene Ther 15 2008 877
5. J.T. Mullen, and K.K. Tanabe Viral oncolysis for malignant liver tumors Ann Surg Oncol 10 2003 596
6. P. Li, C.H. Chen, and S. Li Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer Head Neck 2010 Nov 4 [ Epub ahead of print]
7. Y. Woo, K.J. Kelly, and M.M. Stanford Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells Ann Surg Oncol 15 2008 2329
8. Y. Shen, and J. Neumunaitis Fighting cancer with vaccinia virus: Teaching new tricks to an old dog Mol Ther 11 2005 180
9. Y.A. Yu, S. Shabahang, and T.M. Timiryasova Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins Nat Biotechnol 22 2004 313
10. Q. Zhang, Y.A. Yu, and E. Wang Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus Cancer Res 67 2007 10038
11. S.F. Lin, Z. Yu, and C. Riedl Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus Surgery 142 2007 976
12. S.F. Lin, D.L. Price, and C.H. Chen Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo J Clin Endocrinol Metab 93 2008 4403
13. K.J. Kelly, Y. Woo, and P. Brader Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma Hum Gene Ther 19 2008 774
14. Y.A. Yu, C. Galanis, Y. Woo, and N. Chen Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68 Mol Cancer Ther 8 2009 141
15. R.G. Maki Role of chemotherapy in patients with soft tissue sarcomas Expert Rev Anticancer Ther 4 2004 229
16. P. Brader, K. Kelly, and S. Gang Imaging of lymph node micrometastases using an oncolytic virus herpes virus and [F]FEAU PET PLoS One 4 2009 e4789
17. D.H. Kirn, and S.H. Thorne Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer Nat Rev Cancer 9 2009 64
18. S.H. Thorne, T.H. Hwang, and D.H. Kirn Vaccinia virus and oncolytic virotherapy of cancer Curr Opin Mol Ther 7 2005 359
19. D.H. Kirn, Y. Wang, and F. Le Boeuf Targeting of interferon-β to produce a specific, multi-mechanistic oncolytic vaccinia virus PLoS Med 4 2007 e353
20. S.H. Thorne, T.H. Hwang, and W.E. O'Gorman Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 J Clin Invest 117 2007 3350
21. Park B-H, Hwang T-H, Kim S, et al. A Phase I-II clinical trial with JX-594, a targeted and GM-CSF-armed oncolytic poxvirus, by intratumoral injection in patients with liver tumors. In AACR-NCI-EORTC international conference. San Francisco; 2007, October.
22. T.C. Liu, T. Hwang, and B.H. Park The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma Mol Ther 16 2008 1637
23. B.H. Park, T. Hwang, and T.C. Liu Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial Lancet Oncol 9 2008 533
24. S.H. Thorne Immunotherapeutic potential of oncolytic vaccinia virus Immunol Res 50 2011 286
25. A. Worschech, N. Chen, and Y.A. Yu Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy BMC Genomics 10 2009 301
26. I. Gentschev, U. Donat, and E. Hofmann Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68 J Biomed Biotechnol 2010 Epub 2010 Apr 1
27. P. Baril, Y. Touchefeu, and J. Cany Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma J Gene Med 2011 Epub 2011 Oct 26
28. C.J. Breitbach, J. Burke, and D. Jonker Intravenous delivery of a multi-mechanistic cancer targeted oncolytic poxvirus in humans Nature 477 2011 99